Key Takeaways
- Strong quarter, broad-based growth: Revenue grew 14% YoY to INR896 crore, with domestic business up 17% and international crossing INR400 crore quarterly run rate.
- Margins expanded sharply: Gross margins rose 270 bps to 65.4% on mix, sourcing, and raw material softening; EBITDA margin guidance held at 25-27% with a bias to the higher end.
- Chronic portfolio is the engine: Chronic contribution reached 54-55% of domestic business, outpacing the chronic IPM by a wide margin, with a stated target to reach 60%.
- CDMO in a sweet spot: The business grew 20% and management sees sustained healthy double-digit growth ahead, though a firmer view depends on the upcoming winter season's secondary demand.
- What to watch next quarter: Whether CDMO order book commentary firms up in September after partner indications, the pace of Azmarda volume stabilization post the 50% price cut, and progress on US ANDA approvals.
Domestic Business & Brand Performance
- Chronic leadership: The chronic portfolio continues to outpace the chronic IPM by a wide margin, with most acquired brands now completing one full year in the JB portfolio. Chronic contribution shifted from 53% to 54-55%, with a stated ambition to reach 60%.
- Market-beating trajectory: As per IQVIA MAT June 2023, JB grew 20.7% vs 10.6% for the IPM. In July, when the market showed 6% growth, JB grew at 11%, making it the fastest-growing company in the top 25. Management expects to beat the India pharma market by 300-400 bps for the next three quarters.
- Razel gaining traction: Monthly sales of the recently acquired Rosuvastatin portfolio jumped from an INR5.5 crore average in FY22 to INR6.7 crore in June 2023. The strategy is to shift prescriber base from physicians toward cardiologists for the combination portfolio. Management is confident of at least double-digit growth vs flat growth over the prior three-year CAGR.
- Azmarda volume dynamics: The 50% price reduction in December 2022 triggered a rapid sequential volume ramp-up of 20-25% month-on-month, which is now stabilizing. The market remains attractive with massive uptick in adoption across cardiologists and physicians, and management believes the market can potentially double or triple in the next 2-3 years. The price reduction itself reflects the market opportunity: diagnosis rates did not increase overnight, only the affordability factor changed.
- Sporlac scaling: The probiotic brand scaled from INR60-65 crore to approximately INR90 crore through JB's distribution strength, synergy, prescriptions, and lifecycle management. The broader portfolio of half a dozen brands is growing at mid-teens.
- Go-to-market evolution: Contribution is tilting toward metro and Tier 1 markets as heart failure and specialty portfolios require more specialist prescriptions vs generalist reach. MR productivity improvement plan targets INR7 lakhs from INR6.2 lakhs.
Kunal Khanna: "The sharp price, which you saw with the price reduction itself is a reflection of what the market opportunity is really. And whatever change you have seen over the past 5 months to 6 months has not happened because systemically the market has changed."
International Business & CDMO
- International crosses INR400 crore: International operations grew 11% YoY to INR407 crore, with international formulations up 12% to INR275 crore. CDMO achieved 20% growth, delivering close to INR120 crore in the quarter.
- CDMO sweet spot: Management describes the business as being in a "very sweet spot" with partners of two decades plus. New geographies were added with existing partners, and new products and new partners are in the pipeline with more color expected in the next 3-4 months. The order book for Q2 is healthy, but a firmer view of the next 10-12 months depends on watching seasonal trends and partner indications in September.
- South Africa transformation: The business is going through a transformation with choices made on certain product portfolios in the public business, which impacted overall international formulation growth. The strategy is to be slightly more aggressive in launches to improve the private mix.
- Russia cautious stance: The business grew at mid-teens last year, but management is taking a cautious approach: optimizing existing resources, not investing further, and being conservative on launches. Secondary demand is holding up despite uncertainties, though forex remains a concern. A conservative hedging policy is maintained, and even the 2022 war situation did not significantly impact results.
- Philippines JV: A press release was issued for a joint venture in the Philippines, where JB was historically present through distributors. The intent is to establish direct presence, with opportunity on both institutional and B2C sides.
- US pipeline: Four ANDA filings were completed last year. The next 12-14 months are about ensuring approvals come through, while maintaining a run rate of two to three filings per year. In ROW markets, approximately 10 products were filed last year.
Nikhil Chopra: "We are in a very sweet spot in terms of what we have got very good partners, and the relationship has been here for the last now 2 decades plus."
Margins & Efficiency
- Gross margin expansion: Gross margins expanded 270 bps to 65.4%, driven by three factors: business mix improvement (chronic performance, focus on private market in South Africa), sourcing initiatives on Azmarda and the rest of the portfolio, and raw material cost softening. Management expects to sustain the 65-66% range.
- Operating margin drivers: Operating margins improved on account of better business mix, increased efficiency, in-sourcing, and higher volumes. Logistics and trade costs have stabilized, providing additional margin benefits.
- EBITDA margin guidance held: Guidance continues at 25-27%, with management expressing a preference to be on the higher side of the range. All three aspects (top line, mix, and efficiency) have worked in the company's favor.
- Cash flow inflection: The company expects to become cash positive in FY23-24.
Nikhil Chopra: "We'll be more than happy to be on the higher side of the range. But all the three aspects have worked for us in terms of top line and in terms of mix, in terms of efficiency, that is where we stand as a company. So our guidance continues to be between 25% to 27% of EBITDA margin."
Portfolio & M&A Strategy
- Revenue mix target: The endeavor remains to drive India and CDMO combined to contribute 75-80% of revenues.
- M&A evaluation framework: Management evaluates assets on four aspects: ability to grow the asset at a better pace, ability to improve gross margins through better sourcing or in-house API manufacturing, synergies in consumer therapy areas, and financial discipline. The appetite can go up to 1.5% of EBITDA absolute as a threshold, though this is not hard and fast and depends on asset quality. The payback period target is close to six years.
- No pressure to acquire: Management is explicit that there is no pressure to do M&A just for the sake of doing an acquisition.
- Sanzyme portfolio: The acquired Pubergen and Gynogen business represents approximately 20% of the acquired portfolio. Teams cover approximately 1,500 infertility clinics, products are well accepted by IVF specialists, and JB has also launched supportive therapies for infertility.
- Reckitt partnership: The relationship where JB could not manufacture Strepsils was concluded, with lifecycle management done. The partnership has been extended to Strepsils Immune.
- Lozenges capacity: De-bottlenecking of packaging lines is underway, with packaging capacity reaching 14 crore and a target of 18-20 crore over the next 12 months.
Nikhil Chopra: "There is no pressure on us to do any M&A just for the sake of doing an acquisition."
API & Other Segments
- API business declined 40% YoY: The decline was due to postponement of some orders with one key customer. Management expects to cover the major part of the muted Q1 trend over the second half of the year, noting that H2 tends to be much higher traditionally.
- Rantac volumes: Flat YoY in Q1.
- NLEM price cut impact: Very marginal impact on Metrogyl, described as "very-very marginal" with nothing material to comment on.
- India market volume context: The broader market was probably flat or negative in volume for the first 4-5 months.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India business growth | Beat IPM by 300-400 bps | Next three quarters |
| International business growth | Double-digit growth | Ongoing |
| EBITDA margin | 25-27% range, bias to higher side | Ongoing |
| Gross margin | 65-66% range | Ongoing |
| Chronic contribution | Reach 60% of domestic business | No date (in progress) |
| Razel growth | At least double-digit vs flat prior 3-year CAGR | Ongoing |
| API recovery | Cover major part of Q1 muted trend | H2 FY24 |
| US ANDA filings | Maintain run rate of 2-3 filings per year | Ongoing |
| US approvals | Ensure approvals come through on 4 filings from last year | Next 12-14 months |
| Lozenges packaging capacity | Reach 18-20 crore from current 14 crore | Next 12 months |
| Cash flow | Become cash positive | FY23-24 |
| M&A payback threshold | Close to six years; appetite up to 1.5% of EBITDA absolute | Ongoing discipline |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | ₹896 cr, +14% YoY |
| Domestic revenue | ₹489 cr, +17% YoY |
| International revenue | ₹407 cr, +11% YoY |
| International formulations revenue | ₹275 cr, +12% YoY |
| CDMO revenue | ~₹120 cr, +19% YoY |
| Gross margin | 65.4%, +270 bps YoY |
| Operating EBITDA (ex-ESOP) | ₹243 cr, +28% YoY |
| Operating EBITDA margin (ex-ESOP) | 27.1%, +290 bps YoY |
| Profit after tax | ₹142 cr, +35% YoY |
| Employee cost as % of sales | 16.6%, improved from 17.1% YoY |
| Other expenses as % of sales | improved by ~100 bps YoY |
| IQVIA MAT growth (J.B. vs IPM) | 20.7% vs 10.6% |
| Chronic portfolio contribution (domestic) | 54–55%, up from ~53% last year |
| Razel monthly sales (June 2023) | ₹6.7 cr, up from ₹5.5 cr monthly avg in FY22 |
| Azmarda market share | 16–18% |
| Sporlac portfolio revenue | ~₹90 cr, acquired at ₹60–65 cr |
| Rantac monthly run rate | ₹15–16 cr, volumes 45–50 lakh units |
| API business sales | -40% YoY |
| Lozenges capacity utilization (manufacturing) | ~11 cr lozenges out of 18 cr capacity |
| EBITDA margin guidance (FY24) | 25–27% |
| Domestic growth guidance | beat IPM by 300–400 bps |